药品集采首提“反内卷” 不再唯低价马首是瞻

Group 1 - The article emphasizes the importance of avoiding excessive competition in drug procurement, suggesting that low bids may appear attractive but can lead to inferior quality, ultimately being less cost-effective [1] - It advocates for optimizing the benchmark pricing in bidding processes to ensure that pharmaceutical companies can maintain profitability [1] - The article stresses the need for careful oversight in the selection of medications under the healthcare insurance plan, highlighting the importance of prioritizing quality for the benefit of the public [1]